TY - JOUR
T1 - A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries1
AU - Curtis, Jeffrey R.
AU - Jain, Archana
AU - Askling, Johan
AU - Bridges, S. Louis
AU - Carmona, Loreto
AU - Dixon, William
AU - Finckh, Axel
AU - Hyrich, Kimme
AU - Greenberg, Jeffrey D.
AU - Kremer, Joel
AU - Listing, Joachim
AU - Michaud, Kaleb
AU - Mikuls, Ted
AU - Shadick, Nancy
AU - Solomon, Daniel H.
AU - Weinblatt, Michael E.
AU - Wolfe, Fred
AU - Zink, Angela
N1 - Funding Information:
This work was supported by the Doris Duke Charitable Foundation . Some of the investigators receive support from the National Institutes of Health ( AR053351 : J.R.C.; AR047782 and AG027066 : D.H.S.).
PY - 2010/8
Y1 - 2010/8
N2 - Purpose: Randomized controlled trials (RCTs) have demonstrated the efficacy of biologic agents in the treatment of rheumatic diseases. However, results from RCTs may not be generalizable to clinical practice because of their strict inclusion and exclusion criteria. Assessment of safety using RCT data also is limited by short duration of follow-up and relatively small sample sizes, which generally preclude analysis of longer term outcomes and rare adverse events. In rheumatology, various observational cohorts and registries have been created to complement information obtained from RCTs, some with the primary purpose of monitoring effectiveness and safety of biologic agents. Most registries are either drug based or disease based. These registries include patients with a variety of rheumatic diseases including RA. Methods: To provide a qualitative comparison of selected U.S. and European rheumatoid arthritis (RA) biologics registries and cohorts including ARTIS, BIOBADASER, BSRBR, BRASS, CLEAR, CORRONA, NDB, RABBIT, SCQM, and VARA. Results: A careful comparison of these registries, as provided in this article, can provide a basis for understanding the many similarities and differences inherent in their design, as well as societal context and content, all of which can significantly impact their results and comparisons across registers. Summary: The increasing use of biologic agents for treatment of rheumatic diseases has raised important questions about cost, safety, and effectiveness of these agents. The unique and variable features of patient populations and registry designs in Europe and the U.S. provide valuable and complementary data on comparative effectiveness and safety of biologic agents to what can be derived from RCTs.
AB - Purpose: Randomized controlled trials (RCTs) have demonstrated the efficacy of biologic agents in the treatment of rheumatic diseases. However, results from RCTs may not be generalizable to clinical practice because of their strict inclusion and exclusion criteria. Assessment of safety using RCT data also is limited by short duration of follow-up and relatively small sample sizes, which generally preclude analysis of longer term outcomes and rare adverse events. In rheumatology, various observational cohorts and registries have been created to complement information obtained from RCTs, some with the primary purpose of monitoring effectiveness and safety of biologic agents. Most registries are either drug based or disease based. These registries include patients with a variety of rheumatic diseases including RA. Methods: To provide a qualitative comparison of selected U.S. and European rheumatoid arthritis (RA) biologics registries and cohorts including ARTIS, BIOBADASER, BSRBR, BRASS, CLEAR, CORRONA, NDB, RABBIT, SCQM, and VARA. Results: A careful comparison of these registries, as provided in this article, can provide a basis for understanding the many similarities and differences inherent in their design, as well as societal context and content, all of which can significantly impact their results and comparisons across registers. Summary: The increasing use of biologic agents for treatment of rheumatic diseases has raised important questions about cost, safety, and effectiveness of these agents. The unique and variable features of patient populations and registry designs in Europe and the U.S. provide valuable and complementary data on comparative effectiveness and safety of biologic agents to what can be derived from RCTs.
KW - Cohort
KW - Epidemiology
KW - Registry
KW - Rheumatoid arthritis
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=77955284927&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955284927&partnerID=8YFLogxK
U2 - 10.1016/j.semarthrit.2010.03.003
DO - 10.1016/j.semarthrit.2010.03.003
M3 - Article
C2 - 20674669
AN - SCOPUS:77955284927
SN - 0049-0172
VL - 40
SP - 2-14.e1
JO - Seminars in Arthritis and Rheumatism
JF - Seminars in Arthritis and Rheumatism
IS - 1
ER -